First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study
Ian W. Flinn, Richard Van Der Jagt, Brad Kahl, Peter Wood, Tim Hawkins, David MacDonald, David Simpson, Kathryn Kolibaba, Samar Issa, Julie Chang, Judith Trotman, Doreen Hallman, Ling Chen, John M. Burke
Dive into the research topics of 'First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study'. Together they form a unique fingerprint.